公开(公告)号：US20210172019A1

公开(公告)日：2021-06-10

申请号：US16770351

申请日：2018-12-06

申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) ,  Université de Montpellier ,  Institut Régional du Cancer de Montpellier

发明人： Alain THIERRY ,  Cynthia SANCHEZ

IPC分类号： C12Q1/6886 ,  C12Q1/6806

摘要： The present invention relates to the diagnostic of cancerous subject. Indeed, the inventors observed by using a Q-PCR based methods and sequencing methods that quantification of specific single stranded DNA fragments obtained from cell free nucleic acids (cfDNA) may discriminate cfDNA from healthy and cancer derived subjects. Single stranded DNA fragments obtained from CfDNA or specific range of single stranded DNA fragments are rather lower or higher when derived from healthy subject than from cancer subject. More, specific ratios for different size or range of single stranded DNA fragments varies between cancer subjects and healthy individuals. These values are sufficiently and significantly different to be used as values to determine whether a human subject may have cancer or not as a screening test. Thus, the invention relates to a method for screening a subject for a cancer comprising the steps of extracting and denaturing cfDNA, determining the single strand fragment level upon their size distribution, and calculate these former values to screen an individual for cancer.

公开(公告)号：US20210130847A1

公开(公告)日：2021-05-06

申请号：US16604648

申请日：2018-04-11

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ D'EVRY-VAL-D'ESSONNE ,  GENETHON ,  FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA ,  FONDAZIONE TELETHON

发明人： Federico Mingozzi ,  Giuseppe Ronzitti ,  Andrea Contestabile ,  Laura Cancedda

IPC分类号： C12N15/86 ,  C12N15/113 ,  A61K45/06

摘要： An RNA interference (RNAi) strategy is provided based on use of artificial microRNA (amiR) to reduce NKCC1 expression. In particular, a method is provided that achieves neuron-specific expression of specific amiR against NKCC1 by using a human Synapsin promoter to drive transgene expression.

公开(公告)号：US20210107952A1

公开(公告)日：2021-04-15

申请号：US16500494

申请日：2018-04-03

申请人： TARGEDYS ,  INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ DE ROUEN

发明人： Serguei FETISSOV ,  Grégory LAMBERT ,  Romain LEGRAND ,  Nicolas LUCAS

IPC分类号： C07K14/415 ,  A23L33/16 ,  A23L33/12

摘要： Methods of treating inflammation, in particular obesity, inducing satiation, prolonging satiety, and stimulating weight loss in a subject in need thereof, including the administration of a Brassicaceae protein extract. The Brassicaceae protein extract may be administered in the form of a dietary supplement or a food composition, either of which may include at least one additional ingredient.

公开(公告)号：US10961580B2

公开(公告)日：2021-03-30

申请号：US15537337

申请日：2015-12-18

申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) ,  Université de Nantes ,  Centre Hospitalier Universitaire de Nantes

发明人： Sophie Brouard ,  Magali Giral ,  Richard Danger

IPC分类号： C12Q1/68 ,  C12P19/34 ,  C12Q1/6883 ,  G01N33/50

摘要： The invention relates to a method for predicting graft alterations in a transplanted patient, comprising a step of determining the expression levels of bactericidal/permeability-increasing protein (BPI), chemokine (C motif) ligand 1 (XCL1) and thioredoxin domain containing 3 (TXNDC3) genes in a biological sample obtained from said transplanted patient.

公开(公告)号：US20210087230A1

公开(公告)日：2021-03-25

申请号：US16772178

申请日：2018-12-14

申请人： UNIVERSITE DE STRASBOURG ,  INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)

发明人： VINCENT MARION

IPC分类号： C07K7/08 ,  C12N9/12 ,  A61P1/16 ,  A61K38/45

摘要： The present invention relates to peptides for the treatment or prevention of nonalcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), hepatic steatosis (fatty liver), liver inflammation, cirrhosis, hepatocellular carcinoma or fibrosis, especially liver fibrosis.

公开(公告)号：US10955535B2

公开(公告)日：2021-03-23

申请号：US15512377

申请日：2015-09-25

申请人： CENTRE NATIONAL DE LA RE-CHERCHE SCIENTIFIQUE—CNRS ,  INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)

发明人： Mickaël Tanter ,  Bruno-Félix Osmanski ,  Mathieu Pernot ,  Jean-Luc Gennisson

IPC分类号： G01S7/52 ,  A61B8/00 ,  A61B8/08 ,  G01S15/89

摘要： According to the invention, n incident acoustic waves Ei(t), obtained by linearly combining n elemental incident waves E0i(t) with an encoding matrix Hc are consecutively transmitted in a medium to be imaged. n reverberated waves Ri(t) from the medium to be imaged are then consecutively detected, following the transmission of the n incident waves; then n elemental reverberated waves R0i(t) are determined by linearly combining the detected n reverberated waves Ri(t) with a decoding matrix Hd. The Hc and Hd matrices are such that Hc·Hd=D, where D is a diagonal matrix of order n, all the diagonal elements of which are greater than 1.

公开(公告)号：US20210080467A1

公开(公告)日：2021-03-18

申请号：US16971386

申请日：2019-02-20

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ PAUL SABATIER TOULOUSE III ,  CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE

发明人： Céline COLACIOS VIATGÉ ,  Caroline IMBERT ,  Bruno SEGUI ,  Nicolas MEYER ,  Laurence LAMANT-ROCHAIX ,  Thierry LEVADE ,  Nathalie ANDRIEU-ABADIE

IPC分类号： G01N33/574 ,  G01N33/533

摘要： Immune checkpoint inhibitors (ICI) have revolutionized therapy for advanced cancer, however many patients still do not respond to treatment. However, the efficacy and effectiveness of these therapies varies greatly across individual patients and among different tumour types. A substantial unmet need is thus the development of biomarkers of response to ICI, in order to identify, before initiation of treatment, which patients are likely to experience a response to and clinical benefit from such treatments. Here, the inventors analyzed SPHK1 mRNA in tumor biopsies by in situ hybridization using the RNAscope technology in a cohort of 32 patients suffering from metastatic melanoma. They showed that elevated expression of SPHK1, encoding sphingosine kinase 1 (SK1), which produces the oncometabolite sphingosine-1-phosphate (S1P) is associated with a poor survival in metastatic melanoma patients treated with to the well-known immune-checkpoint inhibitor anti-PD-1 antibody. Accordingly, the present invention relates to the use of SK1 as biomarker for predicting response to immune-checkpoint inhibitors.

公开(公告)号：US10948498B2

公开(公告)日：2021-03-16

申请号：US14910715

申请日：2014-08-08

申请人： INOTREM ,  APHP (ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS) ,  INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ DE LORRAINE

发明人： Marc Derive ,  Sebastien Gibot ,  Hafid Ait-Oufella ,  Amir Boufenzer ,  Tabasomme Simon ,  Nicolas Danchin

IPC分类号： G01N31/00 ,  G01N33/53 ,  G01N33/68 ,  G01N33/566

摘要： A cardiovascular event or disease is prevented or treated in a subject by measuring the expression level of soluble Triggering Receptors Expressed on Myeloid cells-1 (sTREM-1) level in a sample from the subject and comparing it to a reference level. Based on this comparison, subjects that are at risk of having or developing a cardiovascular event or disease are identified, and administered a suitable therapy.

公开(公告)号：US20210023209A1

公开(公告)日：2021-01-28

申请号：US16981462

申请日：2019-03-15

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITE DE PARIS ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS

发明人： Roberto MALLONE ,  Yann VERDIER ,  Joëlle VINH ,  Marie-Eliane AZOURY ,  Sergio GONZALEZ-DUQUE ,  Georgia AFONSO

IPC分类号： A61K39/395 ,  C07K14/47 ,  C07K14/725 ,  C12N15/115 ,  C12N15/62

摘要： Despite the notion that human CD8+ T cells are the final mediators of autoimmune β-cell destruction in type 1 diabetes (T1D), none of their target epitopes has been demonstrated to be naturally processed and presented by β cells. The inventors therefore performed an epitope discovery study combining HLA Class I peptidomics and transcriptomics strategies. Inflammatory cytokines increased β-cell peptide presentation in vitro, paralleling upregulation of HLA Class I expression. Peptide sources included known β-cell antigens and several insulin granule proteins. PCSK2 was identified as a novel β-cell antigen, which was processed into HLA-A2-restricted epitopes recognized by circulating naïve CD8+ T cells in type 1 diabetic and healthy donors. Accordingly, the present invention relates to antigenic peptides derived from PCSK2 and uses thereof for the diagnosis and treatment of T1D.

公开(公告)号：US10894042B2

公开(公告)日：2021-01-19

申请号：US15525771

申请日：2015-11-10

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ PARIS DIDEROT—PARIS 7

发明人： Alain Couvineau ,  Valérie Gratio ,  Pascal Nicole ,  Thierry Voisin

IPC分类号： A61K31/49 ,  A61K31/47 ,  A61K45/06 ,  A61K31/435 ,  A61K31/5513 ,  A61P35/00 ,  A61K31/472 ,  A61K31/551

摘要： The present invention relates to methods and pharmaceutical compositions for the treatment of cancer. More particularly, the present invention relates to a method of treating cancer in subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one OX1R antagonist.